A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Key Points • A new TMTV/ECOG-PS prognostic score was validated in 2174 patients of all ages with DLBCL treated in clinical trials and real-world series.• The combined TMTV and ECOG-PS prognostic score allows identification of patients with high-risk DLBCL before first-line treatment.

[1]  L. Pierce,et al.  A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA , 2022, EJHaem.

[2]  Fanny Orlhac,et al.  A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies , 2021, The Journal of Nuclear Medicine.

[3]  I. Buvat,et al.  Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  B. Cheson.  Predicting the future for DLBCL. , 2020, Blood.

[5]  L. Vercellino,et al.  High total metabolic tumor volume at baseline predicts survival independent of response to therapy , 2020 .

[6]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[7]  R. Boellaard,et al.  Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. , 2019, European journal of cancer.

[8]  Sally F Barrington,et al.  Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden , 2019, The Journal of Nuclear Medicine.

[9]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Klapper,et al.  Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[12]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[13]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[14]  L. Sehn,et al.  Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study , 2017 .

[15]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[16]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Greil,et al.  Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Salles,et al.  Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Gascoyne,et al.  The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[21]  S. Barrington,et al.  Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Pierre Vera,et al.  Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma , 2015, Clinical Cancer Research.

[23]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Federica Fioroni,et al.  Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[27]  S. Barrington,et al.  PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. , 2013, Blood.

[28]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[29]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[30]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[31]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[32]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[33]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[34]  R. Gascoyne,et al.  Clinical Trials and Observations , 2005 .

[35]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[40]  R. Gascoyne,et al.  Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. , 2015, Blood.

[41]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.